AGP Stock Overview
AGP Limited manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan.
AGP Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||PK₨77.00|
|52 Week High||PK₨129.60|
|52 Week Low||PK₨72.00|
|1 Month Change||-6.38%|
|3 Month Change||-11.71%|
|1 Year Change||-39.89%|
|3 Year Change||19.38%|
|5 Year Change||n/a|
|Change since IPO||-8.33%|
Recent News & Updates
|AGP||PK Pharmaceuticals||PK Market|
Return vs Industry: AGP underperformed the PK Pharmaceuticals industry which returned -25.8% over the past year.
Return vs Market: AGP underperformed the PK Market which returned -14.2% over the past year.
|AGP Average Weekly Movement||3.4%|
|Pharmaceuticals Industry Average Movement||3.4%|
|Market Average Movement||4.9%|
|10% most volatile stocks in PK Market||7.8%|
|10% least volatile stocks in PK Market||3.2%|
Stable Share Price: AGP is less volatile than 75% of PK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AGP's weekly volatility (3%) has been stable over the past year.
About the Company
AGP Limited manufactures, sells, wholesales, distributes, exports, imports, markets, deals in pharmaceutical and healthcare products under licensing arrangements in Pakistan. The company offers products in the areas of aminoglycosides, angiotensin II antagonist, anti epileptics, anti-gout, anti-infective antidiarrheal, anti-inflammatory enzyme, antidiarrheal microorganisms, antifibrinolytic, antihistamines systemic, antileuk anti-ashtm sys, antineoplastic agent, anti-obesity, antirheumatic non-steroid, antispasmodic and anticholinergic plain, biguanide and S-urea combs, bile stone therapy, calcium, calcium channel blocker, cephalosporins oral and inject, DPP-IV Inh and biguanide comb, DPP-IV Inh A-diab plain, expectorants, eye tonics and eye vitamins, fluoroquinolones, glitazone and biguanide combinations, hepatitis C antivirals, iron combination products, muscle relaxants central, narcotic analgesic, and non-narcotic analgesic. It also provides SGLT2 inhibitors antidiabetic and biguanide, psycholeptic antidepressant, nucleoside reverse transcriptase inhibitors, Oth folic acid, stomach disorder products, proton pump inhibitor, SSRI antidepressants, sulphonylurea, systemic vasoprotectives, tonic, topical antihaemorrhoidal, urinary anti-infectives, urinary incontinence prd, vitamin B12, vitamin D3, and xanthine-systemic products.
AGP Limited Fundamentals Summary
|AGP fundamental statistics|
Is AGP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGP income statement (TTM)|
|Cost of Revenue||PK₨6.12b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||6.30|
|Net Profit Margin||13.79%|
How did AGP perform over the long term?See historical performance and comparison